Stay Informed
Latest News & Updates
Stay Informed
Latest News & Updates
Jupiter Endovascular Appoints Catalin Toma, MD, as Chief Medical Officer
MENLO PARK, Calif. – August 13, 2026 – Jupiter Endovascular, Inc. a medical technology company developing a new class of endovascular interventions based on its proprietary Transforming Fixation (TFX) technology, today announced the appointment of renowned...
Jupiter Endovascular Announces Positive Results from SPIRARE II Pivotal Trial at EuroPCR 2026
Vertex™ Pulmonary Embolectomy System demonstrated significant heart recovery, low adverse event rates, and reproducible performance across high-severity PE patients MENLO PARK, Calif. – May 20, 2026 – Jupiter Endovascular, Inc. today announced that the SPIRARE II...
Jupiter Endovascular Announces Completion of Enrollment in SPIRARE II Pivotal Trial
Trial Evaluates Safety, Right Heart Functional Improvement, and Clinical Outcomes of Vertex Pulmonary Embolectomy System with Transforming Fixation (TFX) MENLO PARK, Calif. – February 4, 2026 – Jupiter Endovascular, Inc., a medical technology company developing a new...
Jupiter Endovascular Announces Positive Results from SPIRARE I First-In-Human Study Presented at TCT 2025
Vertex Pulmonary Embolectomy System with Transforming Fixation (TFX) Technology Demonstrates Excellent Safety, Performance and Cardiac Recovery MENLO PARK, Calif. – October 26, 2025 – Jupiter Endovascular, Inc., a medical technology company developing a new class of...
Jupiter Endovascular Closes Oversubscribed Series B Financing, Surpassing $40 Million Target
Round Led by Sonder Capital with Participation from Senvest Management, LB Investment, and a New Strategic Corporate Investor MENLO PARK, Calif. - October 7, 2025 – Jupiter Endovascular, Inc., a medical technology startup developing a new class of endovascular...
Jupiter Endovascular Appoints Fred Ong as Chief Financial Officer
MENLO PARK, Calif. - February 26, 2025 – Jupiter Endovascular, Inc., a medical technology startup transforming endovascular medicine with a new class of interventions, announced today that experienced medtech finance and operations executive Fred Ong has joined the...
Jupiter Endovascular Announces First U.S. Patient Treated With Vertex Pulmonary Embolectomy System Using Endoportal Control
SPIRARE II U.S. Pivotal Trial Commences Studying System Designed to Bring the Precision and Control of Direct Surgical Access to Catheter-Based Interventions MENLO PARK, Calif. - October 25, 2024 – Jupiter Endovascular, Inc., a medical technology startup developing a...
Jupiter Endovascular Announces First Patients Successfully Treated In First Clinical Study Of Vertex Pulmonary Embolectomy System Using Endoportal Control
Vertex System Designed to Bring the Precision and Control of Direct Surgical Access to Catheter-Based Interventions MENLO PARK, Calif. - September 19, 2024 – Jupiter Endovascular, Inc., a medical technology startup developing a new class of endovascular procedures...
Jupiter Endovascular Receives FDA Approval for U.S. Pivotal Study of Vertex Pulmonary Embolectomy System Using Endoportal Control
MENLO PARK, Calif. - August 29, 2024 – Jupiter Endovascular, Inc., a medical technology startup developing a new class of endovascular procedures using Endoportal ControlTM to bring the precision and control of direct surgical access to catheter-based interventions,...
Jupiter Endovascular Exits Stealth with $21M in New Financing to Fund Pivotal Trial For Pulmonary Embolism
Carl J. St. Bernard Appointed as Chief Executive Officer MENLO PARK, Calif., August 15, 2024 – Jupiter Endovascular, Inc., a medical technology startup developing a new class of endovascular procedures using Endoportal ControlTM to bring the precision and control of...